AVDL Relative Valuation
AVDL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AVDL is overvalued; if below, it's undervalued.
Historical Valuation
Avadel Pharmaceuticals PLC (AVDL) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 131.80. The fair price of Avadel Pharmaceuticals PLC (AVDL) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：21.36
Fair
30.89
PE
1Y
3Y
5Y
Trailing
Forward
27.72
EV/EBITDA
Avadel Pharmaceuticals PLC. (AVDL) has a current EV/EBITDA of 27.72. The 5-year average EV/EBITDA is 22.67. The thresholds are as follows: Strongly Undervalued below -0.27, Undervalued between -0.27 and 11.20, Fairly Valued between 34.14 and 11.20, Overvalued between 34.14 and 45.60, and Strongly Overvalued above 45.60. The current Forward EV/EBITDA of 27.72 falls within the Historic Trend Line -Fairly Valued range.
28.03
EV/EBIT
Avadel Pharmaceuticals PLC. (AVDL) has a current EV/EBIT of 28.03. The 5-year average EV/EBIT is 86.53. The thresholds are as follows: Strongly Undervalued below -177.48, Undervalued between -177.48 and -45.48, Fairly Valued between 218.54 and -45.48, Overvalued between 218.54 and 350.54, and Strongly Overvalued above 350.54. The current Forward EV/EBIT of 28.03 falls within the Historic Trend Line -Fairly Valued range.
6.09
PS
Avadel Pharmaceuticals PLC. (AVDL) has a current PS of 6.09. The 5-year average PS is 4.84. The thresholds are as follows: Strongly Undervalued below 1.67, Undervalued between 1.67 and 3.26, Fairly Valued between 6.42 and 3.26, Overvalued between 6.42 and 8.00, and Strongly Overvalued above 8.00. The current Forward PS of 6.09 falls within the Historic Trend Line -Fairly Valued range.
21.78
P/OCF
Avadel Pharmaceuticals PLC. (AVDL) has a current P/OCF of 21.78. The 5-year average P/OCF is 32.54. The thresholds are as follows: Strongly Undervalued below -69.40, Undervalued between -69.40 and -18.43, Fairly Valued between 83.50 and -18.43, Overvalued between 83.50 and 134.47, and Strongly Overvalued above 134.47. The current Forward P/OCF of 21.78 falls within the Historic Trend Line -Fairly Valued range.
21.99
P/FCF
Avadel Pharmaceuticals PLC. (AVDL) has a current P/FCF of 21.99. The 5-year average P/FCF is 29.26. The thresholds are as follows: Strongly Undervalued below 4.06, Undervalued between 4.06 and 16.66, Fairly Valued between 41.85 and 16.66, Overvalued between 41.85 and 54.45, and Strongly Overvalued above 54.45. The current Forward P/FCF of 21.99 falls within the Historic Trend Line -Fairly Valued range.
Avadel Pharmaceuticals PLC (AVDL) has a current Price-to-Book (P/B) ratio of 21.14. Compared to its 3-year average P/B ratio of 15.85 , the current P/B ratio is approximately 33.41% higher. Relative to its 5-year average P/B ratio of 15.85, the current P/B ratio is about 33.41% higher. Avadel Pharmaceuticals PLC (AVDL) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -5.14%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -5.14% , the current FCF yield is about -100.00% lower.
21.14
P/B
Median3y
15.85
Median5y
15.85
1.64
FCF Yield
Median3y
-5.14
Median5y
-5.14
Competitors Valuation Multiple
The average P/S ratio for AVDL's competitors is 0.00, providing a benchmark for relative valuation. Avadel Pharmaceuticals PLC Corp (AVDL) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 54.86%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of AVDL increased by 103.19% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -2.99K to -7.43K.
The secondary factor is the Revenue Growth, contributed 54.86%to the performance.
Overall, the performance of AVDL in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Avadel Pharmaceuticals PLC (AVDL) currently overvalued or undervalued?
What is Avadel Pharmaceuticals PLC (AVDL) fair value?
How does AVDL's valuation metrics compare to the industry average?
What is the current P/B ratio for Avadel Pharmaceuticals PLC (AVDL) as of Dec 05 2025?
What is the current FCF Yield for Avadel Pharmaceuticals PLC (AVDL) as of Dec 05 2025?
What is the current Forward P/E ratio for Avadel Pharmaceuticals PLC (AVDL) as of Dec 05 2025?